YNICL Journal 2019 Journal Article
Rasagiline, a monoamine oxidase B inhibitor, reduces in vivo [18F]THK5351 uptake in progressive supranuclear palsy
- Kok Pin Ng
- Joseph Therriault
- Min Su Kang
- Hanne Struyfs
- Tharick A Pascoal
- Sulantha Mathotaarachchi
- Monica Shin
- Andrea L Benedet
BACKGROUND: F]THK5351 uptake has been shown to be confounded by high monoamine oxidase B (MAO-B) availability across the brain in AD. OBJECTIVES: F]THK5351 uptake in PSP. METHODS: F]THK5351 scan. The baseline and post-rasagiline challenge standardized uptake value (SUV) were generated normalized for patient weight and injected radioactivity. RESULTS: F]THK5351 SUV among PSP individuals were not consistent with the typical pattern of tau aggregates in PSP. CONCLUSIONS: F]THK5351 is not sufficient in quantifying tau aggregates in PSP using the proposed rasagiline dosing regimen.